Quebec men with Benign Prostatic Hyperplasia (BPH) now have access to innovative treatment that increases urine flow within hours
OAKVILLE, ON, Oct. 2, 2012 /CNW/ - Watson Pharma Company today announced that Rapaflo® (silodosin), a new treatment for benign prostatic hyperplasia (BPH), will be listed on the Public Prescription Drug Insurance Plan/Régie de l'assurance maladie du Québec (RAMQ) formulary in the province of Quebec effective Oct. 1, 2012.
Rapaflo, launched earlier this year, is indicated for the treatment of the signs and symptoms of BPH, a common enlargement of the prostate associated with urinary problems such as decreased urine flow and poor bladder emptying. The condition affects 40 to 60 per cent of men over age 60, and can cause serious medical complications and a significant reduction in quality of life.
Rapaflo provides rapid improvement of BPH symptoms, including increased urine flow within two to six hours and significant symptom improvement within three to four days. Rapaflo has reduced cardiovascular side effects because of its high selectivity to the prostate. Treatment with Rapaflo for up to 52 weeks resulted in no significant effect on libido or prostate-specific antigen (PSA).
"Watson is extremely pleased that INESSS has recognized the value of Rapaflo for men with BPH," says Rob Tessarolo, General Manager of Watson Pharma Company. "As the first province to list Rapaflo on its public formulary, Quebec has shown leadership by making this important medicine available to the men who need it."
Watson continues to work with officials in each of the other provinces to provide access to Rapaflo through provincial drug plans for men with BPH.
ABOUT WATSON PHARMA COMPANY
Watson Pharma Company is the newly-formed Canadian subsidiary of Watson Pharmaceuticals, Inc. Established in 2011 and headquartered in Oakville, Ontario, it is engaged in the marketing, sale and distribution of branded pharmaceutical products to the Canadian market. Watson is focused on delivering innovative products that address key therapeutic categories in Urology and Women's Health. As a subsidiary of Watson Pharmaceuticals, it is supported by Watson's sophisticated R&D and manufacturing capabilities, and one of the industry's leading global supply chains. For press release and other company information, visit Watson Pharma Company's website at www.WatsonPharmaCompany.ca.
SOURCE: Watson Pharma Company
For further information:
416.413.4744 / Michelle.email@example.com